Editor's note
In March 2022, six departments including the Central Propaganda Department, China Association for Science and Technology, Ministry of Science and Technology, Chinese Academy of Sciences , Chinese Academy of Engineering , and the Administration of Science, Technology and Industry for National Defense jointly issued "About the Development of the "Most Beautiful Science and Technology Workers" in 2022" "Notice on Learning and Publicity Activities", and have successively launched "The Most Beautiful Science and Technology Workers" learning and publicity activities throughout society.
Recently, the 2022 " most beautiful science and technology workers " promotional topic has been officially launched on the official website of the China Association for Science and Technology, the Online History Museum of the Association for Science and Technology, and the website of the Home of Science and Technology Workers. Focusing on the selection of "most beautiful science and technology workers" in various places, we will successively push the deeds of candidates recommended by national societies and local science and technology associations. Learn the best and strive to be the best, contribute wisdom and strength to high-level scientific and technological self-reliance and self-reliance, and welcome the successful convening of the 20th National Congress of the Communist Party of China with a full mental state and a high-spirited attitude of struggle.
Chang Junbiao, a second-level professor, is a national outstanding professional and technical talent, winner of the National Outstanding Youth Science Fund , a leading talent in the national "Ten Thousand Talents Plan", a young and middle-aged expert with outstanding contributions to the country, , and "Hundreds and Thousands of Talents Project" National-level candidates, national outstanding returnees from overseas studies, and advanced individuals in the national science and technology system’s fight against the COVID-19 epidemic. Behind every achievement, Professor Chang Junbiao’s original intention to serve the country with sincerity is engraved.
Thirty years of hard work, science and technology serving the country and keeping true to the original intention
In 1998, after finishing studying in the United States, faced with the invitation of high salary and favorable working and scientific research conditions in the United States, Chang Junbiao declined without much thought, and resolutely returned to the motherland with his wife and children! “Our country has many treasures!” These words of the instructor, Professor Xie Jingxi, echo in my ears all the time. "Breaking the ice in the research and development of new drugs and engraving the name of the Chinese" and "making original drugs in our own country" are the seeds of Chang Junbiao's dreams that have taken root in his heart when he was in school.
30 years, he has proposed new concepts for antiviral drug design around scientific issues and cutting-edge technologies in drug innovation, breaking through traditional thinking and innovatively utilizing the microenvironment RNA polymerase characteristics during virus replication to make drugs It is specifically activated "in situ" in the target cells and works in situ, and a new design strategy for the nucleoside drug has been developed. Breaking through the bottleneck of drug innovation and solving the problem of nucleoside 3′-position deoxygenation that can block viral replication, but is quickly easily recognized by the virus, resulting in drug resistance and ; through structural design, the stability of the nucleoside molecule is improved and increased half-life , the technology level is internationally leading, and has made important contributions in the field of medicinal chemistry research. Relevant scientific research results have been published in more than 380 academic papers in journals including Science, Nature, JMC, JVI, etc.; 6 monographs have been published; 53 invention patents and 5 implementation patents have been authorized by China, the United States, Japan, and Europe; and won the National Science and Technology Progress Award. There are more than ten national, provincial and ministerial level awards such as the second prize, the second prize of the National Natural Science Award, the China Patent Gold Award, the National Innovation Award , etc. A number of innovative drugs have been developed and successfully transformed through industry-university-research cooperation, helping multiple companies achieve industrial upgrading, improve quality and efficiency, and successfully go on the market. Among them, one category 1.1 innovative drug has been approved for marketing, one innovative drug is undergoing phase III clinical trials, and one innovative drug is undergoing phase I clinical trials.
On July 20, 2021, Azivudine (FNC), a new drug in the treatment of AIDS 1.1 that was developed by Professor Chang Junbiao and led by a team in my country with independent intellectual property rights and global patents, was approved for marketing. The result won the China Patent Gold Award and China's important medical progress in 2021 has been included in the 2021 version of the "China AIDS Diagnosis and Treatment Guidelines", which is expected to end the era of domestic patients relying on imported drugs for treatment, leaving China's mark on the history of international new drug research and development.
Work hard and shoulder the mission of researching new drugs to help "fight the epidemic"
Since the outbreak of the new coronavirus pneumonia, Professor Chang Junbiao has led a scientific research team to actively participate in the front line of science and technology to fight the epidemic, and undertook the national key research and development project (anti-new coronavirus small molecule drugs) research and development), cooperate with relevant units to overcome various difficulties and unfavorable factors, and persist in carrying out anti-COVID-19 drug screening work.It has been confirmed through in vitro and in vivo experiments that FNC has strong anti-COVID-19 activity; through multi-center scientific research and clinical studies, it has been found that FNC has a good therapeutic effect on patients with mild, moderate and severe COVID-19 at a dose of 5 mg per person per day. On April 12, 2020, FNC received Phase III clinical approval from the State Food and Drug Administration for the treatment of COVID-19, and received the attention of the Joint Prevention and Control Mechanism of the State Council as an anti-COVID-19 drug. While assisting the domestic fight against the new coronavirus epidemic, Professor Chang Junbiao actively promoted the clinical trials of FNC for the treatment of mild, moderate and severe patients with new coronary pneumonia abroad. In January and March 2021, it was approved by Russia and Brazil respectively for the treatment of new coronavirus III. Phase 1 clinical approval document.
In October 2021, Professor Chang Junbiao made a special report on the research and development of FNC to relevant central leaders; in the same month, FNC was unveiled at the National “13th Five-Year Plan” Scientific and Technological Innovation Achievements Exhibition as the latest achievement of “scientific and technological anti-epidemic”; in November, FNC was used as a tool to suppress the new coronavirus Representative drugs for virus replication appeared on CCTV news. In January 2022, the Ministry of Foreign Affairs sent a letter of thanks to FNC for providing effective emergency support for staff of my country’s embassies and consulates abroad and business delegations. In view of his outstanding performance in the research and development of drugs to treat COVID-19, Professor Chang Junbiao was commended by the National Science and Technology System as an Advanced Individual in the Fight against the COVID-19 Epidemic, and his laboratory was awarded the National Science and Technology System’s Advanced Collective Commendation in the Fight against the COVID-19 Epidemic.
Source: Publicity and Culture Department of China Association for Science and Technology, Talent Center
